Sionna Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, specifically targeting the NBD1 domain. The company reports significant operating losses and anticipates needing substantial additional funding to advance its lead dual combination candidate, SION-451 + SION-2222, through clinical trials.
- Key figure
- Net loss $32.4M